Genital herpes simplex virus (HSV) infections continue to be a major public health problem [1] [2] [3] . For the immunocompetent, recurrences are self-limiting, but in the immunocompromised, untreated mucocutaneous HSV infections can be chronic and progressive [4, 5] . Acyclovir is a potent and selective antiviral that has been the reference standard of treatment and prophylaxis in both host populations [6] [7] [8] [9] [10] . Antiviral resistance has been associated with significant clinical disease progression in~5% of immunocompromised hosts [11] [12] [13] [14] [15] . With one notable exception [16] , immunocompetent and acyclovir-naive patients have been spared clinically significant resistance [17, 18] .
A deficiency in viral thymidine kinase (tk), the enzyme required for selective initial phosphorylation of acyclovir before cellular kinases convert it to the active triphosphate, accounts for the overwhelming majority of instances of resistance [19] . Detection of tk activity at low levels by existing techniques may lead to difficulty in discrimination between tk-deficient (tk D ) and tk-negative (tk-) phenotypes. For this discussion, tkrefers to that subset of isolates in which tk activity is not present (lack of tk activity is absolute), while tk" refers to isolates in which tk activity is undetectable by conventional means. There may be uncertainty concerning subthreshold enzyme activity expressed by tk D isolates. Isolates that are tk? have been shown to be able to establish and maintain latency but demonstrate a loss of efficiency of latency reactivation as well as diminution of neurovirulence in mice [20] [21] [22] [23] [24] [25] . Virulence reductions of such strains has been used to explain the relative absence of acyclovir resistance in the immunocompetent [19] . There has been only one other report of spontaneous clinical reactivations of acyclovir-resistant HSV-2 in AIDS patients. This was an observation of drug-free first reactivations after foscarnet therapy in a clinical trial that did not assess tk activities or viral heterogeneity [26] . Accordingly, it was of interest to extensively characterize an acyclovir-resistant HSV -2 isolate obtained from an AIDS patient with genital herpes who was receiving no antiviral therapy at the time.
Case Report
The patient was a 45-year-old woman with a history of genital HSV since 1984 that she episodically self-medicated with oral acyclovir. In 1985, she was found to be positive for human immunodeficiency virus antibody. Her human immunodeficiency virus disease was subsequently manifested by cervical carcinoma, recurrent pelvic infections, and two episodes of Pneumocystis carinii pneumonia. By September of 1989, her CD4 cell count was 30/ mrrr' and she was admitted after an episode of genital herpes unresponsive to 4 weeks of oral acyclovir (up to 800 mg orally four times daily) and 3 weeks of intravenous acyclovir (10 mg/kg every 8 h). Clinical isolates from this outbreak were acyclovirresistant and tk" and included 1106 (acyclovir ID so , 8.4 p,g/mL; tk activity, 0.6%). Treatment was changed to foscamet, 60 mg/kg every 8 h for 14 days, with full clinical and virologic resolution oflesions. A briefrecurrence in November with acyclovir-sensitive virus responded to oral acyclovir. Further acyclovir-resistant, tk" recurrences soon followed in January, April, and May 1990, each in the setting of acyclovir therapy and also responding to foscarnet. The patient was then prescribed foscarnet prophylaxis in reducing dosages until a further uncultured recurrence in July 1990 was effectively treated with three doses of 60 mg/kg foscarnet every 8 h. She then decided to cease all therapy.
In August 1990, 7 weeks after cessation of all antivirals and after documentation of mucocutaneous healing at two office visits, the patient was readmitted with neurologic complications and was noted again to have an acyclovir-resistant, tk? genital recurrence (clinical isolate 1737: acyclovir ID so, 6.6 f..lg/mL; tk activity, 9.7%). She was treated for only 3 days because of foscarnet-induced symptomatic hypocalcemia but had a satisfactory clinical and virologic response and was discharged receiving no further antiviral treatment. In September 1990, she sustained another recurrence that was acyclovir-sensitive (clinical isolate 1773: acyclovir ID so, 0.11 f..lg/mL; tk activity, 198.6%). The patient died in December 1990 of causes unrelated to her genital HSV infection.
Materials and Methods
Virologic studies. Clinical isolates were obtained On human foreskin fibroblasts and identified and typed as described [27] . Virus stocks were grown in Vero cell monolayers and then titered by serial dilution in 24-well plates. Drug susceptibility was assayed by plaque reduction on Vero cell mono layers to determine IDsos compared with drug-free wells using 24-well plates inoculated with 50 pfu/well overlaid with medium containing drug dilutions and anti -HSV -1 polyclonal antibody (Dako, Glostrup, Denmark), as modified from a previously described technique [28] . Resistance to acyclovir and foscamet was defined as an ID so >2.0 and > 100 f..lg/mL, respectively. A single round of 20 plaque purifications was done by a modification of a previously described technique [29] , using three dilutions in 6-well plates overlaid with medium containing 0.5% agarose. tk activities were determined by measuring the uptake of l-f3-Darabinofuranosyl-E-5-(2-12sIiodovinyl)uracil C 2s IVaraU; 2200 Cil mmol) by human foreskin fibroblasts infected with the strain of interest compared with wild type HSV -2 reference strain G (American Type Culture Collection, Rockville, MD) and tk" reference strain ACG r4 (gift of Don Coen, Harvard Medical School, Boston). Polystyrene tissue culture tubes (16 X 125 mm) containing~3 X io' fibroblasts in 2.0 mL of 5% MEM were inoculated at an MOl of 0.1 and 2 X 10 6 cpm of 12sIVaraU 12 h before the assay. After media removal, monolayers were washed 4 times with 4 mL of PBS, pH 7.4, at 37°C and removed with trypsin, and counts were expressed as a percentage of uptake compared with that of control strain G.
Plaque autoradiography was done by a modification of the method of Martin et al. [30] , using 100 pfu inoculated onto 60 X 15 mm Petri dishes seeded with 2 X 10 6 Vero cells or 4 X 10 6 143B cells (cellular tk "). After a 1-h adsorption, monolayers were overlaid with 0.5% methylcellulose-containing media and incubated for 3-4 days. The overlays were removed, and media containing 0.5 f..lCi of C 2s I]iododeoxycytidine or C 4 C]thymidine (to exclude thymidine kinase-altered phenotype) was added to Vero or l43B cells, respectively, for a further 4 h. Cells were fixed with 10% formalin, stained with 0.5% crystal violet, washed twice with PBS, and air-dried. Circumferential rims were then removed, and monolayers were exposed to radiographic film (Kodak X-Omat XAR) for 5 days and developed. The number of plaques on monolayers was then compared with the number with incorporated radionuclide on autoradiographs as designated by the formation of dark rims at the periphery of plaques.
Mouse neurovirulence studies. Mice were inoculated by the intranasal route as described [31] . Briefly, 4-week-old female BALB/c mice were lightly anesthetized with methoxyflurane (Pitman-Moore, Mississauga, Canada). The appropriate virus inoculum was injected in 20 f..lL of 5% MEM. Inocula of 10'-10 6 pfu were used for each strain, and 6 mice were inoculated at each inoculum. Strains tested included plaque-purified isolates from the spontaneously reactivated tk", acyclovir-resistant isolate (1737-14) and the subsequent posttreatment tk wild type (tk W T ) , acyclovirsensitive isolate (1773-5). Controls included the tk W T reference strain G, tk" reference strain ACG r4, and sham-inoculated animals. Mice were then observed for evidence of encephalitis for 21 days. The brains of dying tk"-inoculated mice were removed, homogenized, sonicated, and cocultivated on Vero cell monolayers. At 30 days, surviving mice were sacrificed. Trigeminal ganglia of 10 such mice inoculated with the two highest inocula of 1737-14 were removed, minced, and cocultivated on Vero cell monolayers. Output isolates from the animal experiments were recharacterized by susceptibility testing, tk uptake, and plaque autoradiography, as described above.
Immunoprecipitation. Identification of tk protein was done by immunoprecipitation using an anti-HSV-2 tk monoclonal antibody (provided by Ken Powell, Burroughs Wellcome, Beckenham, UK). Briefly, 60 X 15 mm culture dishes were inoculated with an MOl of 0.1 and adsorbed for 1 h. The infected monolayer was washed three times with 1 mL of methionineand cysteine-free Dulbecco's MEM (DMEM), overlaid with 5 mL of mixture containing a 9: 1 ratio of methionine-and cysteine-free DMEM to regular DMEM, 4% dialyzed fetal calf serum, and 50 f..lCi/mL Trans 3sS label (1101 Ci/mmol; ICN Biomedicals, St. Laurent, Canada) and incubated overnight. The monolayer was then washed with 2 mL of ice-cold PBS. Cells were lysed with I mL of cold lysis buffer for 15 min On ice and removed with a cell scraper, and nuclei were removed by centrifugation at 15,000 rpm for 5 min at 4°C.
The supernatant was incubated with 100 f..lL of 10% NP-40, 10% Na deoxycholate, and 1% SDS together with 11100 dilution of tk antibody and incubated overnight on ice. Immune complexes were collected by addition of 100 f..lL of a 10% suspension of Staphylococcus aureus cells, rocking at 4°C for 2 h, and centrifugation at 12,000 rpm for 1 min. The pellet was washed sequentially with 0.5 mL of the following solutions: wash buffer 1 (20 mM TRIS-HCI, pH 7.5, 150 mMNaCl, 1% NP-40), wash buffer 2 (20 roM TRIS-HCI, pH 8.8, 150 mM NaCI, 1% NP-40, 0.2% SDS), and wash buffer 3 (20 mM TRIS-HCI, pH 6.8, 150 mM NaCl, 1% NP-40, 0.2% SDS). The pellet was then resuspended in 50 f..lL of SDS sample buffer (2% SDS, 5% 2-mercaptoethanol, 62.5 mM TRIS-HCl, pH 6.8,10% glycerol, and 0.001% bromophenol blue), denatured at 100°C for 5 min, and electrophoresed at 25 rnA for 4 h through a 6% stacking and 10% resolving acrylamide gel. Gels were then fixed in 40% methanol and 5% acetic acid, dried, and exposed to radiographic film.
Results
The acyclovir-resistant, tk D clinical isolate that reactivated spontaneously (1737) was characterized further to determine the reason for its reactivation ability. An acyclovir-sensitive isolate from the next reactivation (1773) served as an internal control. Initially, plaque isolations were done in an attempt to demonstrate heterogeneity within clinical isolates. Nineteen plaque isolates were successfully regrown from 1737 and recharacterized. Each was acyclovir-resistant with acyclovir IDsos ranging from 2.1 to 17.1 I-Lg/mL. Individual plaque isolates from both 1737 (1737-14: acyclovir ID so, 11.8 I-Lg/rnL; tk activity, 5.4%; foscamet ID so, 30.9 I-Lg/mL) and 1773 (1773-5: acyclovir ID so, 0.14 I-Lg/mL; tk activity, 134.7%; foscamet ID so, 34.0 I-Lg/mL) were then selected for animal model studies. More rigorous assessments of heterogeneity by plaque autoradiography demonstrated 1737 and 1773 and their respective plaque isolates (1737-14 and 1773-5) all to be homogeneous populations (figure 1).
Because heterogeneity did not seem to underlie the reactivation ability of 1737, we attempted to determine whether this unusual characteristic ofthe isolate was paralleled by increased neurovirulence. Accordingly, 1737-14 was assessed for neurovirulence and latency characteristics in the mouse modeL No animals administered an inoculum of> 10 2 pfu of tk W T strains G or 1773-5 survived, while all animals inoculated with tk? strain ACGr4 and all sham-inoculated animals survived. As predicted by its tk D phenotype, 1737-14 overall showed reduced neurovirulence, with all animals administered inocula up to 105 pfu surviving. Surprisingly, however, 1 of 6 mice inoculated with 10 6 pfu died from encephalitis. Recharacterization of this encephalitic output strain, 1737-14ME, showed it to be fully acyclovir-sensitive (acyclovir ID so , 0.12 t-tg/mL; tk activity, 154.9%), and plaque autoradiography demonstrated a homogeneous tk W T population (figures 1 and 2). In contrast, virus recovered by co cultivation from trigeminal ganglia of 2 of the surviving mice inoculated with 1737-14 yielded strains that were acyclovir-resistant and had reduced tk activities (l737-14/10 6A; 1737-14/10sB). Strain 1737-14/ 10 6A (acyclovir ID so, 9.0 t-tg/mL; tk activity, 8.9%; foscamet ID so, 11.8 j.lg/mL) was similar to the acyclovir-resistant, tk D phenotype of the input strain 1737-14, but strain 1737-14/1 OSB (acyclovir ID so, 15.2 fLg/mL; tk activity, 53.5%; foscamet ID so, 9.7 t-tg/mL), despite acyclovir resistance, demonstrated a surprisingly high level of tk uptake. Plaque autoradiography demonstrated strain 1737-14/1 0 6 A to be a homogenous tk D population similar to the input strain, but strain 1737-14/1 OSB was an almost equal heterogeneous population of tk" and tkWT plaques (figures 1 and 2); this correlated with the unexpectedly high tk activity. Foscamet susceptibility excluded a mutation in the viral DNA polymerase locus.
Immunoprecipitation demonstrated 1773-5 to produce a fulllength 40-kDa tk protein identical to that of tk W T reference strain G, while 1737-14 produced a truncated 28-kDa protein but no full-length tk product; this is consistent with a protein lacking tk activity (figure 3).
Discussion
This is the first report that documents, characterizes, and provides the mechanistic basis for a spontaneous clinical reactivation of an acyclovir-resistant HSV isolate that tests as tk" by all conventional assays. Resistance was acquired during the treatment of previous episodes and then reactivated without selection pressure by continuing antiviral administration. Complete eradication of HSV from the affected area between episodes was well-documented, demonstrating that latent acyclovir resistance had been induced.
The behavior of this isolate and its reactivation in the patient appeared paradoxic in the face of current dogma suggesting that tk" HSV should not be able to reactivate. Although tk uptake studies may have suggested a low level of activity, this assay has proved insensitive in discriminating between low and absent activity. Plaque autoradiography demonstrated a homogeneous tk" population, while immunoprecipitation showed it to produce a truncated protein in the absence of any detectable full-length tk protein, this more accurately reflecting its phenotype. Despite its apparent absence of tk activity, however, 1737-14 resulted in mouse encephalitis with a pure tk W T population, while trigeminal ganglia latency was due to mixed tk phenotypes. It is very likely that the tk activity demonstrated in the neurovirulence studies also enabled clinical isolate 1737 to reactivate. This work further enhances the principle that tk activity is required for reactivation of HSV.
It has been previously documented that the tk activity of an isolate correlates well with the proportion of tkWT virus within a mixed population [30] and that mutants with low levels of tk activity can reactivate from latency [32] . These data suggest that very sensitive tk assays challenge old phenotypes and demonstrate that the levels oftk expression necessary for reactivation are quantitatively much lower than previously appreciated. Indeed, these data demonstrate that tk activity may fall below the threshold of conventional assays. In this case, tk activity was amplified using passage in the animal model. Figure 2 . Derivation of HSY-2 plaque isolate 1737-14 tracing input and output strains from mouse neuroviru1ence studies. Schematic demonstrates how reactivated tk-deficient (tk") clinical isolate 1737 underwent plaque purification to produce plaque isolate 1737-14, both of which appear as homogeneous tk" populations by plaque autoradiography. After inoculation of 1737 -14 into mouse model, neurovirulent brainderived output strain, 1737-14ME, was homogeneous tk wild type (tk?"), while latent virus strains successfully recovered from trigeminal ganglia of 2 surviving mice (l737-14110 6A and 1737-141l0 5B) consisted of homogeneous tk" and heterogeneous tkWT/tk D populations, respectively. JID 1996;174 (September) Herein, we have designated such strains' 'ultralow" tk producers. The distinction between isolates with very low levels of tk activity as opposed to true absolute tk deficiency remains confused. Our data suggest that the tk activity of such isolates may represent a continuum, based on the proportion of tkWT virus, with the threshold for reactivation yet to be determined.
The ability of such a small tkWT subpopulation to impart their characteristics on an overwhelmingly larger tk D population to enable it a wider phenotypic expression by reactivating suggests that in vivo complementation between the populations may be occurring. If complementation explains these events, it would further suggest that this phenomenon would be capable of selectively dissociating the tk phenotypic expressions of reactivation and neurovirulence from others by still testing as tk", acyclovir-resistant by all conventional tests. Subpopulations ofHSV polymerase mutants have previously been demonstrated to confer the acyclovir-resistant phenotype on a larger acyclovir-sensitive population and result in clinical disease progression [33] . Evidence for complementation has been previously documented in HSV between temperature-sensitive mutants [34, 35] , neuroinvasive mutants [36] , and pairs of tk mixed strains [37] . Some, but not all, instances of complementation are due to genetic recombination [34] [35] [36] . Because the tk protein exists as a homodimer, it has also been proposed that a heterodimer may form in which a wild type polypeptide may compensate for the activity of a mutated partner [38] . Finally, there may simply be local exchange of phosphorylated nucleotide pools. The existence and mechanism of complementation in this instance remains speculative.
There are two possible explanations for the emergence of tk W T virus within these apparently pure populations: Either a very small preexisting tk W T population, undetectable by conventional means, became unmasked because of the exquisite sensitivity of the animal model in amplifying virus or in vivo reversion to tk W T took place. The natural frequency ofreversion of the tk gene has been estimated at 10~4 to 1O~6 [39] . Recent work has demonstrated that 1737-14 contains a frameshift mutation at a site that is a mutational "hot spot" [40] , suggesting that much higher reversion frequencies at such sites, combined with a possible growth advantage of tk W T over tk", may allow for the emergence of such subpopulations. If that is the case, then a plaque isolate completely devoid of tk activity may be unachievable from a clinical isolate regardless of the number of rounds of plaque purification.
The issue of whether tk activity can be dissociated from neurovirulence has also been recently debated. Erlich et a1. [14] and Chatis and Crumpacker [41] reported a plaque-purified tk? HSV isolate from an AIDS patient that, due to a single base substitution, produced a full-length protein and retained full neurovirulence. Plaque autoradiography in those studies, however, was done in a tk-producing cell line using a [ 14 C]thymidine overlay, potentially reducing assay sensitivity in demonstrating heterogeneity or a tk low-producer phenotype. In addition, the combination of a full-length tk polypeptide and a base substitution that is not in any of the three described conserved binding domains [42] calls into question the significance of this mutation. Contrary to this, the isolate from the current report demonstrated neurovirulence, as predicted, to be directly linked to tk activity. The possibility that masked heterogeneity, as seen here, was present but not tested in the previous report must be considered and may have provided sufficient tk activity to explain the observed neurovirulence.
The clinician must appreciate that effective clinical and virologic eradication of mucocutaneous viral shedding through foscarnet (or alternative) therapy, followed by no antiviral treatment whatsoever, may still eventuate in reactivation of acyclovir-resistant isolates in a subsequent episode. Accordingly, the use of acyclovir may, in some cases, fail even for treatment of a new and unchallenged recurrence. Nevertheless, normal tk activity prevailed in the majority of untreated reactivations. Presumably, clones expressing tk were more efficient reactivators. That withdrawal of acyclovir pressure in this patient eventually led to an acyclovir-sensitive, tkWT reactivation further supports this hypothesis. Alternatively, tk W T reactivations may have originated from different latently infected ganglion sites altogether that had not been subjected to the development of resistance. Regardless of the underlying mechanism, for patients with refractory disease, this reversion of HSV over time to an acyclovir-sensitive population is reassuring in that, at least initially, acyclovir may be useful in such instances. Alternating acyclovir and foscarnet or other such combination may thus be a useful strategy in the control of resistant disease.
